Skip to the story
Morning ColumnFree letter

Current News · Sourced report

FDA Provides Clarity to Support Cell and Gene Therapy Development and Quality

The U.S. Food and Drug Administration today issued final guidance for manufacturers of cellular and gene therapy (CGT) products to implement a comprehensive, science- and risk-based plan for making sure their products me

News Desk · Nov 2, 2026 · U.S. Food and Drug Administration

Open the source

This item is a public release from the U.S. Food and Drug Administration. The source date is Nov 2, 2026. The next paragraph is the agency's own short text. Morning Column did not rewrite it.

The U.S. Food and Drug Administration today issued final guidance for manufacturers of cellular and gene therapy (CGT) products to implement a comprehensive, science- and risk-based plan for making sure their products meet potency standards.

The full release is on the source page. This page is not personal medical advice.

This page is general information from the sources below. It is not personal medical advice, a diagnosis, or a treatment plan. Talk with a qualified clinician about your own health. Read the disclaimer.

References

  1. U.S. Food and Drug Administration. FDA Provides Clarity to Support Cell and Gene Therapy Development and Quality. Nov 2, 2026.

See a factual error? Write to contact@morningcolumn.com. The corrections log is public.